Why the study?
Does 3,4-Dihydro-1-isoquinolineacetamide hydrochloride (DIQA) demonstrate antiviral activity against various viruses in vitro, in ovo, and in vivo?
Does 3,4-Dihydro-1-isoquinolineacetamide hydrochloride (DIQA) demonstrate antiviral activity against various viruses in vitro, in ovo, and in vivo?
DIQA demonstrates selective in vivo antiviral activity against several viruses, despite lacking corresponding in vitro efficacy for most of these strains.
Answers are grounded in this paper and cite their sources.
DIQA's selective in vivo antiviral activity suggests no immediate clinical role; leaves open mechanistic questions requiring higher-evidence validation.
3, 4-Dihydro-1-isoquinolineacetamide hydrochloride (DIQA) is a novel antiviral agent active in vivo against Columbia SK virus, herpesvirus, ECHO 9 virus (Coxsackie virus A23) and the PR8 and Japan 305/57 strains of influenza A virus. The substance was without effect in vivo against Coxsackie virus B1, Newcastle disease virus and influenza B virus. The compound was inactive when tested in tissue cultures against the viruses for which it had an antiviral effect in vivo. It was also inactive in tissue cultures against poliovirus type I and measles virus. Activity in vitro could be detected against Coxsackie virus B1 and vaccinia virus but, in the latter case, only if a plaque-reduction method was employed. The antiviral agent did not display anti-influenza activity in ovo.
No takes yet. Share an insight, caveat, or question.
Grunberg et al. (1968) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: